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Abstract 
Despite significant improvement in weight and comorbid conditions, there is growing 
evidence that bariatric surgery may exert a negative effect on the skeleton. This review has 
focused on the impact of bariatric surgery on bone health, with the concern that bariatric 
surgery may increase skeletal fragility and fracture risk by accelerating bone loss. We have 
highlighted studies evaluating changes in bone metabolism after three commonly performed 
bariatric procedures including laparoscopic adjustable gastric banding, Roux-en-Y gastric 
bypass surgery and increasingly popular sleeve gastrectomy. This review has also discussed 
some of the technical issues faced in measuring bone in obese populations and during 
dynamic weight loss. There is limited evidence regarding potential mechanisms for the 
reported observations of increased bone turnover and/or bone loss after bariatric surgery. We 
have reviewed the evidence surrounding potential factors affecting bone health in bariatric 
patients such as rapid weight loss per se, nutritional deficiencies, effects of fat-derived 
adipokines and gut-derived appetite-regulatory hormones. Future prospective long-term 
cohort studies are needed to define how to quantify bone loss in individuals with obesity, 
particularly following massive weight loss, and for how long the bone changes continue. These 
studies will help clarify any negative clinical consequences of these changes, including future 
fracture risk in this unique group of patients. 
 
Introduction 
The prevalence of obesity worldwide has increased significantly in recent decades because of a 
complex range of environmental and possibly also epigenetic factors. Obesity is associated 
with increased mortality [1] with reduced life expectancy, especially amongst people affected 
from young adulthood [2], as well as multiple comorbidities including type 2 diabetes, 
hyperlipidemia, sleep apnoea, malignancy and decreased quality of life [3]. 
 The medical management of obesity is limited by the variable, limited response to 
treatment, suboptimal compliance and adverse effects of antiobesity medications. At present, 
the only effective, long-term treatment for obesity remains bariatric surgery, which results in 
substantial and sustained weight loss, significant reductions in comorbid conditions, and 
prolonged longevity [4]. In fact, the utilization of bariatric surgery as a therapeutic approach 
to morbid obesity has increased two and a half-fold worldwide between 2003 and 2011 [5]. 
 Although many studies have demonstrated the short- and long-term efficacy of 
bariatric surgery for weight loss, there are limited data regarding any long-term side effects of 
these procedures. Recently, there has been an increased focus on the impact of bariatric 
surgery on bone metabolism, with the concern that bariatric surgery may increase skeletal 
fragility and fracture risk by accelerating bone loss. 
 The majority of research performed in this area has been cross-sectional and provides 
little evidence as to the possible mechanisms for any observed abnormalities in bone 
metabolism with few data documenting longitudinal changes in bone density and bone 
turnover. 
 This review will highlight studies examining the impact of obesity surgery on bone 
metabolism, focussing on the three most commonly performed procedures: laparoscopic 
adjustable gastric banding (LAGB or gastric banding), sleeve gastrectomy and Roux-en-Y 
gastric bypass (RYGB), as well as considering effects of biliopancreatic diversion (BPD) on 
bone. It will then explore potential underlying mechanisms for the reported observations of 
heightened bone turnover or bone loss after bariatric surgery and potential long-term 
consequences of bariatric surgery, including the long-term risk of fracture in this population 
of patients. Before covering these topics, it will first give an overview of the effect of obesity 
(without bariatric surgery) on bone, as well as more detailed information about the various 
bariatric surgery procedures, since both of these issues are relevant to understanding the 
effects of bariatric surgery on bone. 
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Obesity and Bone 
With the increasing prevalence of obesity, one area of research that is beginning to attract 
greater attention is the effect of obesity on bone. Epidemiological evidence suggests that 
obesity is correlated with increased bone mass and that increased body weight protects 
against bone loss [6, 7]. However, despite such evidence of a protective effect of obesity on 
bone, there is increasing evidence that excess weight due to adiposity may be detrimental to 
bone and fracture risk. 
 Osteoporosis and obesity have been shown to coexist, as evident in disorders 
involving fat redistribution such as type 2 diabetes mellitus, Cushing’s disease and drug-
induced lipodystrophies [8]. Indeed, in some cohorts, the per cent of total fat mass is strongly 
and inversely associated with bone mineral density (BMD) [9]. Severe obesity may 
compromise skeletal health in overweight and obese children who have reduced bone area 
and bone mass relative to body weight compared with their leaner peers [10]. Obesity is 
associated with lower serum 25-hydroxyvitamin D and higher serum parathyroid hormone 
levels than in non-obese individuals [11, 12]. Obesity is also associated with 
hypogonadotropic hypogonadism in men [13] and higher circulating concentrations of 
inflammatory cytokines, which are key mediators of osteoclast differentiation through the 
regulation of RANKL/RANK/OPG pathway [14]. Increased production by visceral fat of 
adiponectin and pro-inflammatory cytokines may result in adverse effects on bone [15], as 
demonstrated in obese adolescent and pre-menopausal women [16, 17]. Obese women have 
lower rates of bone formation, as indicated by circulating type I collagen levels, suggesting 
that increased body fat suppresses new collagen formation [18]. 
 Recent evidence indicates that the regulation of adipose tissue and bone is closely 
related [19], since adipocytes and osteoblasts derive from a common mesenchymal stem 
progenitor. Multiple clinical conditions such as osteoporosis and ageing-related bone loss are 
associated with an increase in marrow fat, which suggests a conversion of stromal cells to 
adipocytes rather than osteoblasts [20]. Several studies that examined the function of 
adipocytes in bone marrow and mesenchymal stem cells isolated from bone marrow of post-
menopausal osteoporotic patients found these cells to express more adipose tissue 
differentiation markers than those from subjects with normal bone mass [21]. Increased bone 
marrow fat has been found in subjects with morphologic evidence of bone weakness such as 
endplate depression and compression fractures [22]. Finally, an inverse association was noted 
between vertebral bone marrow fat and trabecular BMD in pre-menopausal obese women 
[17], in keeping with the hypothesis that adipose tissue and bone mass may undergo inverse 
regulation. 
 Besides associations with osteoporosis, low BMD or lower rates of bone formation, 
obesity is also associated with fractures, and not only in older people [23], as there are data to 
show an increased prevalence of forearm fractures amongst obese young adults [24, 25]. Post-
menopausal obesity appears to be a risk factor for fracture at specific sites such as the tibia 
and ankle [25]. In a recent meta-analysis of women with an average age of 63 years, high BMI 
after adjustment for BMD was associated with a higher risk of non-vertebral and all 
osteoporotic fractures [26]. Post-menopausal obesity also appears to be a risk factor for low 
trauma fractures. A study of 799 women with low trauma fracture attending a Fracture 
Liaison Service in the UK found that 28 % of these women were obese. Despite having 
fractured, in the majority of these obese women, BMD was normal as defined as a T-score >−1 
[25]. A subsequent prospective, multinational study of 60,393 women reported similar rates 
of low trauma fractures between obese and non-obese post-menopausal women [27]. These 
findings question the commonly held perception that obesity is protective against 
osteoporosis or low trauma fractures. Moreover, they raise the possibility that low trauma 
fractures are occurring in obese women at a higher BMD than usually recognized as a risk for 
such fractures. 
 As the prevalence of obesity continues to increase, it is important to recognize that 
bone quality may be compromised in obesity and that this population of patients contributes 
significantly to overall fracture burden. 
 
Efficacy of Bariatric Surgery 
Bariatric surgery is generally reserved for patients with a BMI greater than 40 kg/m2, or for 
those with a BMI greater than 35 kg/m2 whose obesity is complicated by one or more major 
diseases such as type 2 diabetes mellitus or sleep apnoea. There are two major surgical 
categories: gastric interventions including LAGB, also known as gastric banding, vertical 
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gastroplasty and sleeve gastrectomy as well as gastrointestinal diversionary procedures such 
as RYGB and biliopancreatic diversion. 
 The first surgical treatment procedure for obesity was performed in 1952 by Viktor 
Henrikson in Gothenburg. This procedure involved resection of a large part of the small 
bowel, creating weight loss through nutrient malabsorption. Other surgical procedures soon 
followed. These early surgeries were complicated by a high frequency of adverse events [28]. 
 Gastric banding surgical techniques evolved during the 1970s with the aim of 
providing a less invasive approach to weight loss. An adjustable band is placed around the 
upper part of the stomach, restricting the amount of food eaten by patients by mechanisms 
that are still not entirely clear. Initially, bands with a fixed diameter were used. The first 
modern adjustable gastric band was invented in 1986 [29], later (1992) applied via a 
laparoscopic approach. Gastric banding procedures accounted for 18 % of all bariatric 
procedures worldwide in 2011, but recently their numbers have declined as the sleeve 
gastrectomy procedure has increased from 0 in 2003 to 27.8 % in 2011 [5]. 
 Sleeve gastrectomy was originally performed as a modification to another bariatric 
procedure, the duodenal switch, and then later as the first part of a two-stage gastric bypass 
operation on extremely obese patients for whom the risk of performing gastric bypass surgery 
was deemed too large. The initial weight loss in these patients was so successful that sleeve 
gastrectomy began to be investigated as a stand-alone procedure. 
 In sleeve gastrectomy, a major part of the greater curvature of the stomach is 
removed, including the complete fundus up to the angle of His, as well as the majority of the 
corpus and antrum. The pylorus function is left intact, enabling a normal outflow of gastric 
contents. The full mechanism of action is still not exactly clear, but restriction of food intake 
through a decrease in gastric volume plays some part. Sleeve gastrectomy also leads to a 
decrease in gastric acid secretion and a faster gastric emptying rate [30], an effect not 
observed in gastric banding [31]. Both of these changes would lead to a faster arrival of 
undigested nutrients in the duodenum, with subsequently increased production of gut 
hormones that modulate perceptions of hunger and satiety after meals. 
 Thirty per cent of all bariatric procedures worldwide are now sleeve gastrectomy, and 
the frequency of this procedure is steadily increasing due to its superior efficacy over gastric 
banding [5]. 
 Roux-en-Y gastric bypass (RYGB) is a gastrointestinal diversionary procedure that 
diverts food from a large portion of the stomach and the proximal small intestine into the 
distal small intestine. It consists of creating a small gastric pouch connected to the small 
intestine via a Roux-en-Y limb [32]. The length of the Roux-en-Y limb is varied to augment 
the degree of malabsorption and subsequent weight loss. It was initially believed that RYGB 
worked solely through malabsorption; however, recent studies have revealed that this surgical 
technique also alters the secretion of several gut hormones that not only alter hunger and 
satiety signalling but which also affect energy expenditure [33, 34]. 
 Bariatric surgical procedures promote substantial weight loss that is rarely achieved 
and even more rarely maintained with nutritional and lifestyle management alone. The 
efficacy of different types of bariatric surgery varies in terms of weight loss achieved and 
improvement in obesity-related comorbidities, as will be outlined below. 
 Weight loss post-bariatric surgery is frequently expressed as per cent loss of excess 
body weight, the latter being defined as the difference between the pre-operative weight and 
ideal body weight (i.e. at a BMI of 25 kg/m2). 
 Gastric banding results in an average loss of 20–30 % of initial body weight [35], 
equivalent to a loss of 41–54 % of excess body weight [36]. Long-term gastric banding data 
indicate that the loss of excess (e.g. 47 % of excess) weight can be maintained up to 15 years 
post-surgery [37]. Sleeve gastrectomy produces an average body weight loss of 20–30 %, 
equivalent to a loss of 45–64 % of excess body weight [35, 38]. After RYGB, patients lose up to 
approximately 35 % of their initial weight, equivalent to a loss of 62–75 % of excess body 
weight, with this loss being maintained at 10–14 years following surgery [36, 39–41]. 
 As well as effects on weight loss and in some cases, even before significant loss of 
excess body weight, bariatric surgical procedures have been shown to resolve or ameliorate 
type 2 diabetes mellitus in 57–86 % of cases, hyperlipidemia in approximately 71 % of cases, 
hypertension in 68 % of cases, and sleep apnoea in 80–85 % of cases, with RYGB having a 
greater beneficial effect on these comorbidities than other bariatric procedures [36, 42]. 
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Effects of Laparoscopic Adjustable Gastric Banding (Gastric Banding) on Bone 
With a paucity of available data, it is currently unclear whether significant effects on bone 
mass occur following gastric banding. All studies to date have been small with a short follow-
up of 24 months or less. 
 Results at both the spine and hip have been equivocal. A study of pre-menopausal 
women found an increase of 3.5 % in BMD in the lumbar spine at 12 months post-gastric 
banding [43], while two other studies reported non-significant increases in lumbar spine 
BMD of approximately 4.0 % in the first 2 years following gastric banding [44, 45]. 
 Bone loss has been reported in the hip after gastric banding in association with 
increased bone turnover markers, but to a lesser extent than with RYGB [43–45]. While 
research in pre-menopausal women suggests that bone loss at the hip site may appear as early 
as 6 months after gastric banding [43, 44], there are more robust data supporting bone loss at 
the first year after surgery, by which time the majority of weight loss has occurred. Giusti et al. 
[43] reported a 2.3 % BMD loss at the hip (femoral neck) at 12 months following gastric 
banding surgery, and 5.8 % BMD loss at 24 months after the procedure. The bone loss in both 
publications [43, 44] from this longitudinal study was associated with an early increase in 
markers of bone resorption (urinary and serum concentrations of type I collagen breakdown 
products), although an absence of secondary hyperparathyroidism suggested that factors 
other than lack of calcium and vitamin D were involved in post-surgical bone remodelling. 
 In contrast to the above studies, a small Swiss pilot study [45] compared the skeletal 
effects of gastric banding (n = 9) with those of RYGB (n = 4) over 24 months, with matched 
morbidly obese men and women in the control arm (n = 6). No significant changes from 
baseline in bone mineral content (BMC) were reported at 24 months in the gastric banding 
and control groups. However, there was a significant decrease from baseline in BMC in the 
RYGB group (p = 0.005), which was accompanied by significant increases in bone turnover 
markers (serum osteocalcin and urinary deoxypyridinoline concentrations). 
 
Effects of Sleeve Gastrectomy on Bone 
There are few available data on changes in bone mass or metabolism following sleeve 
gastrectomy, despite the expansion of this procedure in recent years [46, 47]. To our 
knowledge, there have been three small studies describing skeletal changes post-sleeve 
gastrectomy. 
 One prospective study [48] comparing the effect of sleeve gastrectomy with RYGB on 
bone mass and remodelling found significant bone mass loss in the lumbar spine and hip at 
12 months post-operatively in all surgical patients, relative to baseline values. Bone loss was 
slightly and non-significantly less pronounced in the spine and femur after sleeve gastrectomy 
than after RYGB (4.4 vs 4.6 and 5.4 vs 6.3 %, respectively, for the spine and femur). The urine 
levels of a bone resorption marker, N-terminal telopeptide, were significantly elevated over 
baseline in both surgical groups, consistent with the reported bone loss. 
 Another prospective, 6-month study [49] examined BMD changes in 29 obese women 
with a mean BMI of 43 ± 5 kg/m2 after laparoscopic sleeve gastrectomy and found that their 
BMD decreased by 1.2 % at the lumbar spine, 7.0 % at the femoral neck and 5.2 % at the total 
hip. All differences from baseline were significant. In parallel with these BMD declines, the 
participants’ mean body weight and BMI decreased by 28.4 % after 6 months. The loss of 
BMD at the hip and femoral neck correlated with weight loss (r = 0.48, p < 0.01; r = 0.51, 
p < 0.01, respectively]. The Pluskiewicz study had several limitations including short follow-
up and lack of a control group. Moreover, the study did not include other factors that could 
either influence or support changes in bone metabolism such as bone turnover markers, 
calcium intake and vitamin D. 
 The third study of bone post-gastric sleeve was a retrospective, observational study of 
42 morbidly obese patients. The investigators reported an increase in bone density at the 
spine 2 years post-sleeve gastrectomy [50]. Mean BMD values for spine increased 
progressively, reaching statistical significance at one and at 2 years. The percentage of BMD 
increase was 5.7 % at 1 year and 7.9 % at 2 years. BMD changes were not associated with 
weight loss, but showed a direct correlation with circulating vitamin D and an inverse 
correlation with circulating parathyroid hormone levels. Hip BMD was not measured. The 
researchers concluded that an absence of bone loss at the lumbar spine may be related to an 
effect of parathyroid hormone. Although chronically elevated circulating parathyroid 
hormone levels have catabolic effects on cortical bone, mild increases in this hormone have 
anabolic effects on cancellous bone, which predominates at the spine [51]. The increase in 
lumbar spine bone mineral density was evident in several other bariatric studies in which 
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post-operative parathyroid hormone levels increased [52–54]. 
 Clearly, further work is required to assess the effect of sleeve gastrectomy on bone 
mineral density changes after the bariatric surgery. Notably, studies investigating bone mass 
after bariatric surgery need to investigate multiple sites (i.e. lumbar spine and hip) in order to 
obtain a clearer understanding of possible effects. 
 
Effects of Roux-en-Y gastric Bypass (RYGB) on Bone 
Several studies [45, 52–64] have examined the effects of RYGB for morbid obesity on bone 
mineral density and/or bone turnover. Further corroborating the observed loss of bone, these 
studies have shown alterations in urinary or circulating concentrations of bone turnover 
markers. 
 In brief, these studies show evidence of an early increase in bone remodelling, as 
indicated by an increase over baseline values of circulating or urinary concentrations of bone 
turnover markers including breakdown products of type I collagen (a major organic 
component of bone matrix that is synthesized primarily in bone) such as serum and urinary 
N-telopeptide, C-telopeptide, as well as osteocalcin, a non-collagenous protein secreted 
specifically by osteoblasts. These increments in bone turnover markers over baseline or 
control values vary widely between studies, ranging between 29 and 319 %. They were 
observed as early as 3 months after surgery [45, 52, 55] and occurred in spite of patients 
taking routinely recommended calcium and vitamin D supplements [53–56, 60, 61, 63]. 
 Indices of increased bone turnover have been demonstrated to persist long after the 
RYGB procedure. A recent study documented elevated serum osteocalcin and serum N-
terminal telopeptide concentrations relative to baseline values at 18 months post-RYGB 
surgery [60], indicating a prolonged increase in bone turnover. This observation is consistent 
with a previous report describing raised serum osteocalcin levels in patients examined 
10 years after RYGB [54]. 
 Despite these demonstrations of increased bone turnover, there are inconsistent 
findings of changes in bone mass in subjects post-RYGB surgery. Most [45, 52, 55, 58, 64] but 
not all [53], [54] reports suggest a decline in bone mineral density and bone mineral content 
during the first year post-surgery. Any decreases in bone mass post-RYGB have been observed 
predominantly at the hip, further highlighting the need to investigate both hip and spine 
regions in such research. Further details of these studies will be highlighted below. 
 Many studies investigating body composition post-RYGB have used whole body dual-
energy X-ray absorptiometry (DXA) scanning to assess overall fat, lean and bone mass. While 
such scans are primarily designed for the clinical assessment of bone mass, they nonetheless 
give insights into whole body bone mineral content (BMC), which has been reported to be 
reduced by 3–12 % at 9–24 months after RYGB surgery [52, 53, 55–58, 61]. 
 Prospective studies which assessed changes in BMD up to 3 years [63] after RYGB in 
men, as well as in women in various menopausal stages, reported the greatest BMD reduction 
to be in the femoral neck, where the BMD decline was between 9.2 and 10.9 % compared with 
baseline values [52, 65], and total hip BMD losses ranging from 8 to 10.5 % [58, 63]. 
 The long-term sequelae of RYGB procedures on bone are not known. In particular, it 
is unclear whether the BMD loss post-bariatric procedures continues, stabilizes or reverses. A 
strong association between bariatric surgery and osteoporosis is not supported by the 
literature [66]. Data from 230 patients followed for 3 years after RYGB surgery reported a 
significant one-year total hip BMD decline of 9.3 % without further BMD loss after the second 
and third years, suggesting that bone loss may subside after the first post-surgical year [56]. 
Conversely, a single prospective study of 59 morbidly obese white women aged 46 ± 8 years 
showed that their bone density continued to decline after the first year after RYGB despite no 
further significant weight loss. At 12 months post-surgery, patients’ BMD decreased at the 
femoral neck by 10.2 % and by 3.2 % at the lumbar spine, with an additional BMD decline at 
the femoral neck by 2.7 % and at the lumbar spine by 3.1 % by the third year post-surgery. 
BMD at both sites remained above the population-average values of women of the same age 
[67]. 
 From the above studies, it appears that the clearest declines in BMD after RYGB are 
seen in the hip and femoral neck. However, although some studies showed no significant 
change in lumbar spine BMD after RYGB surgery [52, 53, 64], several other studies have 
reported a significant decline in lumbar spine BMD that varied from 3 to 7 % compared with 
baseline at 9–12 months post-surgery [55, 63, 65], with an additional 3 % decrement in one of 
the studies at 3 years post-surgery [63]. 
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 In obese subjects after bariatric surgery, an important factor influencing bone status 
is the loss of body weight that has been postulated to result in bone loss through an unloading 
effect. Indeed, the decrease in bone mineral density observed in adults after RYGB correlated 
with the amount of lost weight in many studies [45, 52, 58, 62, 64]. 
 Several studies, outlined below, have documented alterations in the calcium–vitamin 
D–PTH axis, together with changes in bone turnover markers suggesting that changes in this 
axis may explain some of the observed bone loss post-RYGB surgery. 
 A prospective study [55] compared bone turnover in 25 patients post-RYGB with that 
of 30 obese control participants. Compared to controls, significant elevations in bone 
turnover markers such as serum osteocalcin and urinary N-terminal telopeptide were 
observed at 3 and 9 months post-operatively, in association with prominent and significant 
decreases in BMD of the total hip (7.8 ± 4.8 %, p < 0.001), trochanter (9.3 ± 5.7 %, p < 0.001) 
and total body (1.6 ± 2.0 %, p < 0.05), as well as significantly reduced BMC at all of these sites 
by 9 months post-surgery. Other assessments of bone and mineral metabolism (i.e. serum 
concentrations of parathyroid hormone and calcium as well as 24-h urinary calcium 
excretion) were not different between controls and post-surgical patients. The post-surgical 
group self-reported significantly higher dietary vitamin D and calcium intakes, suggesting 
that vitamin and mineral supplementation may protect against secondary 
hyperparathyroidism after RYGB surgery. 
 In a recent prospective analysis comparing pre- and post-surgery values, a similar 
bone mineral density loss of 8 % was reported in the hip of 23 patients investigated at 
12 months post-RYGB [52]. In this study, a linear relationship was observed between weight 
loss and the decline in bone mineral density, which was associated with raised bone turnover 
markers relative to baseline (p < 0.01 for both urinary N-terminal telopeptide and serum 
osteocalcin). There was evidence of calcium and vitamin D malabsorption with reduced 
urinary calcium excretion after RYGB, as well as elevated serum concentrations of 
parathyroid hormone and unchanged serum 25-hydroxyvitamin D concentrations. Self-
reported oral vitamin D intake increased by 260 % by 12 months post-surgery. The authors 
concluded that RYGB-related bone loss is associated with alterations in the calcium–vitamin 
D–parathyroid hormone axis, through calcium and vitamin D malabsorption and secondary 
hyperparathyroidism. 
 In accordance with previously described studies [52, 63], a recent study of 22 women 
examined 12 months post-RYGB surgery found that their BMD had decreased by an average 
of 7.26 % in the lumbar spine, by 8.78 % in the femoral neck, and by 8.59 % at total femur, 
with associated hyperparathyroidism and elevated urinary concentrations of the bone 
resorption marker urine N-terminal telopeptide (NTx) [65]. This post-operative bone mass 
loss occurred in spite of a doubling of 25-hydroxy vitamin D intake amongst study patients via 
monitored use of multivitamin supplement and regular doses of cholecalciferol. The achieved 
circulating 25-hydroxy vitamin D levels did not change in the post-operative period despite 
this supervised supplementation [11.7 (9.7 − 18.0) vs 15.7 (10.2-2.7)] pg/dL pre-operatively, 
p   =   0.327], suggesting reduced vitamin absorption or assimilation post-RYGB. 
 Perhaps more troubling than the above reports of RYGB-induced bone loss in adults 
are reports of the potential effect of bariatric surgery on bone mass in younger subjects. 
Currently RYGB remains the most commonly performed bariatric surgical procedure for 
morbidly obese teens in most US centres [68], albeit sleeve gastrectomy has the potential to 
become the preferred surgical intervention in obese adolescents due to its efficacy and fewer 
complications including nutritional deficiencies [69]. A retrospective study [59] of 61 
adolescents at 2 years post-RYGB surgery reported significant post-operative bone loss, with a 
7.4 % decrease in BMC. There was a decline in the Z score for BMD from 1.5 to 0.1; however, it 
still remained within the normal range for gender and age, likely due to the high bone mineral 
content and density before surgery in this extremely obese population. Longer follow-up is 
required to determine whether bone loss in this group of young patients continues, stabilizes 
or reverses. 
 Taken together, these studies show that RYGB surgery induces changes in bone 
remodelling with consistent increase in bone turnover markers and commonly observed bone 
loss, particularly at the hip. The clinical significance of the observed biological and 
radiological changes is unclear. 
 
Effects of Biliopancreatic Diversion (BPD) on Bone 
Current evidence suggests that biliopancreatic diversion (BPD) with duodenal switch is the 
most effective procedure for long-term excess weight loss and reversal of comorbidities [36]. 
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However, the prevalence of this procedure declined worldwide from 4.8 in 2003 to 2.2 % in 
2011 [5] due to the associated risk of severe metabolic abnormalities. Reports addressing 
impact of BPD on bone health are scarce and contradictory. Secondary hyperparathyroidism 
occurs in up to 70 % of BPD patients due to compromised calcium and vitamin D absorption 
[70], with the associated long-term increase in bone turnover markers despite rigorous 
calcium and vitamin D replacement [71]. Subsequently, osteoporosis and osteomalacia may 
develop, as shown by analysis of bone histology at 4 years post-BPD surgery [72, 73]. 
 In contrast to the above studies suggesting bone loss in response to BPD, bone 
biopsies from 33 BPD patients examined 4 years after BPD surgery showed no evidence of 
demineralization, as well as showing an increased bone formation rate and trabecular bone 
volume [74]. Bone mineral density of the hip of these patients was unchanged, but that of the 
lumbar spine was decreased by 4 %. One-third of patients in this study developed secondary 
hyperparathyroidism in spite of monitored calcium and vitamin D supplementation. 
 Comprehensive long-term studies are required to address lifelong sequelae of this 
uncommon, irreversible bariatric BPD procedure and to define the optimum nutritional 
programme required to preserve normal bone mineralization process and prevent the 
potential development of osteoporosis in these patients. 
 
Bariatric Surgery, Bone and Measurement of Bone Mass in Severe Obesity 
It is important to point out that interpretation of the published data about bariatric surgery 
and skeletal health is limited at this stage due to small sample sizes, inconsistent study 
measures, varying degrees of bone loss as well as potential difficulties in the accuracy of 
measurement of bone mass in morbid obesity and during weight loss. 
 The majority of studies have used areal BMD (aBMD; grams per square centimetre) 
as the primary outcome for bone health in post-bariatric patients, as determined by DXA. In 
clinical settings, measurement of aBMD by DXA is accepted as a surrogate marker of bone 
strength and fracture risk [75, 76]. However, this technology is not designed to measure 
geometric or strength changes known or thought to occur subsequent to changes in 
mechanical loading. Furthermore, major changes in fat mass and its distribution may affect 
the precision of BMD measurement in this group of patients, especially when assessing aBMD 
[77–82]. Variability in aBMD increases significantly with tissue depths greater than 25 cm, 
and excess fat around bone can result in overestimation of aBMD in obese subjects [83, 84]. 
Variation in determination of bone area may potentially result in errors in BMD in obese 
subjects [77, 85]. 
 Positioning of obese subjects for scanning is more difficult than for lean people [84], 
and variability in positioning of the fat panniculus affects the accuracy of BMD measurements 
in the hip area. Overlying abdominal pannus can lead to heterogeneity of soft tissue 
composition over the scanned region of interest (ROI) and unpredictable changes in aBMD 
values [86], particularly at the proximal femur. 
 In addition to these technical limitations in obesity, effects of obesity on DXA-based 
measurements of BMD also vary according to the measurement technique, including the type 
of DXA system used, the distribution of body fat, the software used, and scan mode [81]. 
Different DXA manufacturers (GE-Lunar, Norland and Hologic) differ in their methods of fat 
and BMD determination, and direct comparisons across manufacturers are not possible. 
 A recent study by Yu and co-workers [87] quantified bone loss using both DXA and 
quantitative computed tomography (QCT) in 30 obese individuals who lost weight through 
RYGB. The two methods found a similar, 3 % decline in spine BMD yet discrepant results at 
the hip. Analysis of DXA scans identified an up to 9 % decline in total hip BMD, whereas QCT 
detected a more modest loss (3.0–4.5 %) of trabecular bone and negligible total bone loss at 
any hip site. Both methods were probably affected by artefact in this study. The DXA resulted 
in an apparent increase in the area of the bone, while QCT resulted in an apparent decrease in 
measured bone volume. Weight loss will alter the distance between the hip and the X-ray 
source in fan beam DXA scanners resulting in errors in estimation of bone size although not 
BMD. By contrast, applying thresholds to QCT to determine the soft tissue/cortical bone edge 
might have resulted in an apparent decline in volume consequent to a real decline in BMD. 
This artefact would result in bone loss being underestimated with QCT [88]. 
 In recent years, peripheral quantitative computed tomography (pQCT) has been used 
to measure volumetric bone density (vBMD, g/cm3) and mechanically meaningful measures 
of bone geometry, such as bone cross-sectional area and cortical thickness, measurements for 
which strength differences are evident between populations such as athletes and non-athletes 
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or between overweight and healthy weight individuals. Given the planar nature of DXA, pQCT 
provides a more accurate characterization of bone’s three-dimensional structure [89–91]. Yet 
both DXA-based aBMD outcomes and bone strength indices, obtainable by pQCT technology 
have been shown to correlate strongly with fracture risk [92]. 
 High-resolution peripheral quantitative computed tomography (HR-pQCT), contrary 
to DXA, may assess the extent to which cortical and trabecular bone are differentially affected 
after bariatric surgery. The potential advantage of this method has been highlighted by a 
recent study, which used HR-pQCT technology to evaluate changes in vBMD and 
microstructure after RYGB bariatric surgery [64]. This study suggested that RYGB surgery 
primarily affects the cortical bone and that these cortical changes are associated with 
increased parathyroid hormone levels in surgical patients. In contrast, bone loss at the hip in 
this study was primarily associated with weight loss [64]. Further studies are needed to 
corroborate these findings. 
 In summary, technological limitations in obese populations may preclude accurate 
assessments of prospective bone changes with any of the available technologies. Extreme 
obesity and excess fat introduces errors in all BMD measurements and may result in an 
erroneous estimation of the actual decreases in bone density following substantial weight 
reduction [77, 80–82]. Studies evaluating the effects of fat simulation on BMD measurements 
by DXA have reported under- or overestimation in BMD values, depending on the DXA 
scanner model and software used [77, 93]. 
 Taken together, these limitations of areal bone mineral density by DXA need to be 
recognized when exploring models, such as bariatric surgery, where changes occur in the 
mechanical loading environment. The potentially reduced accuracy of DXA measurements in 
extreme obese scenario underlines the need to perform duplicate scans, follow subjects for 
extended periods post-surgery after weight loss has ceased, and consider newer technologies, 
such as pQCT, to further delineate changes in bone volumetric density, geometry and strength 
after bariatric surgery. 
 Moreover, measures of bone mass via DXA or other methods should be supplemented 
with measures of circulating or urinary concentrations of bone turnover markers, to gain a 
deeper level of insight into any effects of obesity or weight loss on bone physiology. 
 
Potential Mechanisms of Bone Loss after Bariatric Surgery 
The cause of the bone mass loss in obese subjects after weight loss has not been fully 
elucidated. Several mechanisms may explain the changes in bone metabolism observed after 
bariatric surgery. 
 In obese subjects after bariatric surgery, one important factor influencing bone status 
is probably loss of body weight, resulting in reduced mechanical load on the skeleton. 
Traditionally, this had been thought to be a major contributor to bone mass loss. However, it 
has recently been reported in adolescents that weight loss accounted for as little as 14 % of 
their loss of BMC after bariatric surgery, suggesting a significant contribution of additional 
factors [59]. Additionally, in another study [94] bone loss was found to be greater in the group 
who lost less weight, suggesting that factors other than weight loss per se were involved in the 
loss of bone. Such factors include pre-existing micronutrient deficiency, post-surgical changes 
in calciotropic hormones as well as changes in gut hormones and hormones derived from 
adipose tissue. These factors will be discussed in greater detail below. 
 Reduced delivery of essential nutrients, including calcium and vitamin D, may be a 
consequence of diversionary bariatric procedures such as RYGB, as well as of the energy 
restriction that follows all successful bariatric operations. Pre-existing alterations in calcium 
homeostasis [95] and vitamin D deficiency, which are common in obese patients [96, 97], may 
further contribute to the development of secondary hyperparathyroidism, which has been 
documented in many [52, 53, 98] but not all studies of bariatric surgery [55, 60]. Such 
deficiencies could conceivably lead to metabolic and skeletal abnormalities including 
fractures. Vitamin D insufficiency as defined by mean 25-hydroxy vitamin D level of < 50 or 
75 nmol/l has been reported pre-operatively in up to 80 % of bariatric patients [99], with 
many patients having suboptimal 25-hydroxy vitamin D up to 10 years post-operatively [100]. 
A review of 14 reports representing data from 1,566 patients found only a single study [101] of 
30 patients which reported a mean 25-hydroxy vitamin D > 80 nmol/l. [99]. This study did 
not report the assay method that was used for vitamin D measurement, making their data 
difficult to evaluate. 
 The majority of reported studies on bariatric surgery have not found any significant 
Brzozowska	  et	  al.:	  Clin.	  Rev.	  Bone	  Miner.	  Metab,	  12(4):	  207-­‐227,	  2014	  
increase in vitamin D status above baseline despite vitamin D supplementation [52, 57, 101]. 
In some studies, although the circulating 25-hydroxy vitamin D levels increased significantly, 
it did not increase to optimal levels [102, 103]. Suboptimal vitamin D would be consistent 
with a consequent unresolved hyperparathyroidism, demonstrated in up to 40 % of bariatric 
patients [102]. Secondary hyperparathyroidism has been demonstrated in up to half of 
patients two years after RYGB surgery [104]. A more recent study of 22 women (mean BMI 
44 kg/m2; mean age 45 years) who underwent RYGB (n = 14) and restrictive procedures 
(n = 8) reported a substantial increase in circulating parathyroid hormone levels, by 23 ± 8 % 
(p < 0.02). Two study subjects (1 RYGB and 1 gastric banding patient) developed secondary 
hyperparathyroidism, which occurred in spite of their pre-operative 25OHD levels being 
within the normal range, monitored calcium and vitamin D supplementation and stable post-
operative serum 25OHD. These findings suggest post-operative depletion in vitamin D and 
calcium secondary to a varying combination of reduced intake, malabsorption and enhanced 
storage of vitamin D by adipose tissue [105, 106] that remains well above normal despite 
adipose tissue loss induced by RYGB surgery. 
 Serious metabolic bone disorders such as osteomalacia have been estimated to occur 
in ~2.5 % of patients following gastric bypass in the United States [107]. The osteomalacia 
and marrow fibrosis which were documented in bone biopsies of five RYGB patients 
considerably improved after therapy with pharmacologic doses of ergocalciferol (100,000 IU 
daily) and calcium carbonate (1–2.5 g daily) [108], highlighting the need for prospective long-
term studies to determine the appropriate vitamin D supplementation required to prevent 
osteomalacia in such patients. 
 Vertical sleeve gastrectomy can also lead to post-operative vitamin D deficiency. In a 
single study of 60 gastric sleeve patients, 39 % had evidence of vitamin D deficiency at up to 
12 months post-surgery despite daily multivitamin supplementation [109]. Restrictive 
procedures like gastric banding also point to vitamin D deficiency being common up to 
2 years after the surgery [110]. 
 Notwithstanding the studies outlined above, the precise impact of micronutrient and 
vitamin deficiencies on bone health in post-RYGB patients has not been well documented, 
partly due to lack of standardized guidelines for the nutritional care and assessment of these 
individuals. Studies have used different post-operative calcium and vitamin D dietary and 
supplementation protocols. Prescribed supplements have varied in dose and, although 
sufficient for a general population, may not be sufficient in bariatric surgery patients. Lack of 
rigorous post-operative follow-up, and varying recommended dosages of calcium and vitamin 
D supplements across studies, might also have contributed to differences in estimated bone 
loss. To our knowledge only two studies [52, 64], which reported evidence of calcium and 
vitamin D malabsorption after RYGB surgery, monitored vitamin D and calcium compliance 
through standardized questionnaires of intake from food sources and supplements. 
 Although the American Society for Metabolic and Bariatric Surgery recommends high 
levels of Ca (1.5–2 g/day) and vitamin D intake (3,000 IU/day) following bariatric surgery 
[111], exact levels associated with beneficial outcomes are not known due to the lack of 
randomized controlled trials. Studies suggest that serum 25-hydroxyvitamin D concentrations 
≥80 nmol/l optimize calcium absorption and suppresses parathyroid hormone secretion; 
however—as seen in the above studies—monitored vitamin D supplementation did not 
mitigate vitamin D insufficiency and observed reductions in BMD [112]. 
 Besides deficiencies in micronutrients, notably calcium and vitamin D as noted above, 
the more radical bariatric surgical procedure of BPD may lead to macronutrient deficiency, 
namely protein malnutrition [113]. Protein-calorie malnutrition is recognized by signs such 
as hypoalbuminemia, oedema, anaemia and hair loss. Hypoalbuminemia has been 
demonstrated in 3.4–18.0 % of patients post-BPD and duodenal switch [113, 114]. 
 Protein deficiency could conceivably contribute to the bone loss that has been 
reported in some [72, 73] but not all [74] studies of patients post-PBD surgery. The positive 
effects of protein intake on bone have been established in several epidemiological and clinical 
studies [115], but the relationship is not strictly linear because some studies have linked 
excessive protein intake with hypercalciuria and an increased risk of fracture [116]. In a 
prospective study of healthy, pre-menopausal women, a low-protein intake of 0.7 g/kg body 
weight was associated with an increase in bone resorption marker of urinary collagen type 1 
cross-linked telopeptide NTX compared with a diet containing 1.0 g/kg of protein [117]. 
Studies indicate that inadequate dietary protein may lead to low calcium absorption and the 
development of secondary hyperparathyroidism with an increased risk of osteoporotic 
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fractures [118]. In the National Health and Nutrition Examination Survey (NHANES I) study, 
hip fractures were associated with low energy intake, low serum albumin levels and low 
muscle strength consistent with protein deficiency [119]. A higher-protein weight loss diet 
may preserve bone mass during caloric restriction by attenuation of decreased circulating 
concentrations of insulin-like growth factor 1 or calcium absorption [120]. 
 The Endocrine Society guidelines suggest that bariatric patients should ingest 60–
120 g of protein daily [121]. A systematic review of protein and bone health concluded that 
diets containing protein at a level of 1.0–1.5 g/kg body weight are optimal for bone health 
[122]. A similar level of protein intake is also considered optimum for appetite control and 
weight management in non-bariatric patients [123]; thus, there are likely to be multiple 
benefits from this recommendation. However, such a protein intake can be difficult for obese 
and morbidly obese patients to achieve on calorie restricted eating plans without rigorous 
attention to dietary choices, let alone for patients with reduced gastric capacity. Thus, 
prevention of protein malnutrition in bariatric patients requires that patients work with 
dieticians to help ensure they meet their dietary requirements. 
 While studies to date have not enabled definitive dissection of the relative 
contribution of changes in nutrient status and/or weight loss to changes in bone after 
bariatric surgery, other studies point to novel potential mechanisms of the change emanating 
from other potential mechanisms, such as the adipose tissue–gut–brain axis. 
 A serious question to be examined is whether hormonal responses to bariatric surgery 
contribute to bone loss. Dietary energy restriction (without bariatric surgery) has been shown 
to induce neuroendocrine changes that would be expected to accelerate bone loss [124]. Such 
changes include reduced circulating concentrations of thyroid hormones, sex hormones and 
insulin-like growth factor-1 alongside increases in circulating cortisol levels [125]. There is 
also a growing body of literature showing that bariatric surgery alters the secretion of 
hormones from adipose tissue (notably the adipokines leptin and adiponectin), bone-derived 
factors such as the osteokine osteocalcin and sclerostin, as well as from the gastrointestinal 
tract (notably the appetite-regulating gut hormones PYY, GLP-1 and ghrelin), all of which 
have been shown to have significant effects on bone homeostasis in recent studies. The 
majority of these data demonstrating involvement of these hormones on bone come from a 
series of elegant gene knockout studies in rodents [126–128]. Current knowledge of the 
extent of their involvement in any bariatric surgery-induced bone loss and the mechanisms 
underlying such effects is limited. 
 For the purpose of this review, we will focus on the appetite-regulating hormones 
originating from the gut, namely peptide YY (PYY), GLP1 and ghrelin, as well as the 
adipokines leptin and adiponectin, the osteokine osteocalcin, as well as sclerostin. 
 
Peptide YY 
PYY belongs to a polypeptide family that also includes neuropeptide Y (NPY) and pancreatic 
polypeptide (PP). PYY is recognized as a critical regulator of food intake and energy 
homeostasis. PYY is released from enteroendocrine L cells lining the distal gastrointestinal 
tract in response to a meal [129, 130]. Circulating PYY is lowest in the fasting state and rises 
postprandially to suppress appetite. Obese subjects have been reported to have significantly 
reduced circulating fasting and postprandial levels of PYY [131]. 
 Postprandial PYY levels have been shown to increase in response to RYGB [132] and 
sleeve gastrectomy [133], while it remains unclear whether gastric banding has any 
comparable effects on fasting or postprandial circulating PYY levels [134]. 
 Recently, an inverse relationship between elevated PYY and both body weight and 
bone loss has been modelled in mice. Transgenic overexpression of PYY in mice was 
protective against diet and genetically induced obesity and demonstrated strong, negative 
effects on bone, resulting in decreased bone formation and increased resorption, with 
opposite effects in PYY null mice [135]. In contrast, a study of an independently generated 
PYY knockout mouse line reported an osteopenic phenotype, with reductions in vertebral 
cancellous bone mass and bone strength [136]. The differences observed between these PYY 
knockout mouse studies might have occurred due to problems with developing genetically 
altered PYY levels in these animals, as PYY overexpression has teratogenic effect on 
embryonic neurogenesis [137]. 
 In humans, several reports point towards an association between elevated PYY and 
low BMD, with PYY being negatively correlated with bone mass in people with normal weight 
and with anorexia nervosa. Consistent with a negative effect of PYY on body weight and bone 
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mass, circulating PYY concentrations are markedly elevated in anorexia nervosa [138], a 
condition well known to be associated with low BMD [139]. Indeed, Utz et al. [139] 
demonstrated that PYY levels were significantly negatively correlated with metabolic and 
skeletal indices. Russell [140] demonstrated PYY to be negatively associated with lumbar 
BMD Z scores and a marker of bone formation, serum type 1 procollagen C-terminal/N-
terminal (PINP) in adolescent female athletes both with and without amenorrhoea. Moreover, 
in lean pre-menopausal women, circulating PYY levels were significantly and negatively 
correlated with total body and hip bone mass, with PYY contributing to 9 % of the variance in 
BMD of the hip [141]. A single clinical study to date has correlated raised postprandial PYY 
levels with bone mineral density loss in bariatric surgery patients (Brzozowska MM, 
Endocrine Reviews 2013: FP09). 
 Future work with formal, standardized protocols is needed to elicit exact 
contributions of these neuroendocrine changes to accelerated bone loss in patients who 
undergo obesity procedures. 
 
GLP1 
GLP1 is a key incretin that, along with PYY, is released from the lower intestinal endocrine L 
cells in response to ingested nutrients [142]. GLP-1 exerts glucoregulatory actions by 
stimulating insulin secretion, slowing gastric emptying and attenuating glucose-dependent 
glucagon secretion [143]. As with PYY, it has been suggested that increased postprandial 
GLP-1 levels may contribute to inducing a signal of satiety within the hypothalamus and 
promoting weight loss [144]. Several studies have shown that the secretion of GLP-1 is 
considerably attenuated in type 2 diabetes [145] and in obesity [146], although contradictory 
findings have also been reported [147]. 
 Relatively few studies have examined changes in GLP-1 concentrations in obese 
patients after bariatric procedures. Patients who underwent gastric banding showed either a 
reduction or no post-surgical change in fasting GLP-1 levels [148–150]. Furthermore, three 
studies that measured the postprandial GLP-1 levels after a meal at up to 12 months post-
gastric banding did not find any significant difference compared to values measured pre-
operatively [150–152]. Similarly for sleeve gastrectomy, fasting GLP-1 levels pre-operatively 
and 3 months post-operatively were similar; however, the postprandial area under the curve 
and peak levels of GLP-1 increased as early as the first post-operative week [153, 154]. Post-
surgical increases in postprandial GLP-1 have been documented following RYGB [150, 155]. 
Augmented levels of GLP-1 may account for the antidiabetic effect of the RYGB procedure, 
which has been reported before any major weight loss has occurred [33, 155, 156]. Thus, 
these data suggest that postprandial—albeit not fasting—circulating levels of GLP-1 may be 
augmented after bariatric procedures, at least sleeve gastrectomy and RYGB. 
 Although osteoblasts express the GLP-1 receptor (GLP-1R), the main action of the 
GLP-1/GLP-1R pathway in bone physiology and bone quality is largely unknown. The 
influence of GLP-1 on bone regulation has been predominantly studied in rodents. GLP-1 
receptor knockout mice have cortical osteopenia and bone fragility, as determined by DXA, as 
well as increased osteoclastic numbers and bone resorption activity as determined by bone 
histomorphometry [157]. Rats treated with GLP-1 for 3 days via subcutaneously implanted 
osmotic pumps displayed elevated expression of osteoblastic genes in bone tissue without any 
change in plasma glucose and insulin after treatment [158]. In this study, these effects were 
true for wild-type mice as well as in rat models with glucose intolerance. 
 The results from these studies point to an insulin-independent anabolic effect of GLP-
1 on bone and suggest that GLP-1 could be a useful therapeutic agent for improving the 
deficient bone formation and bone structure associated with glucose intolerance [158]. 
However, information about the role of GLP-1 in this regard is scanty and has not been 
investigated in human studies. 
 
Ghrelin 
Ghrelin is a potent appetite-stimulating hormone, synthesized in the gastric antrum and 
fundus [159]. The circulating concentrations of ghrelin increase under preprandial and 
fasting conditions, and this change likely contributes to the drive to eat after periods without 
food [160]. 
 Reports of circulating ghrelin levels after bariatric surgery vary, with either no change 
or increases in fasting plasma ghrelin relative to baseline after gastric banding [148, 161]. By 
contrast, a reduction in fasting plasma ghrelin relative to baseline levels was found in one 
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study up to 5 years after sleeve gastrectomy [162]. Inconsistent post-surgical changes in 
circulating ghrelin levels have been found after RYGB, with studies demonstrating a reduction 
[163, 164], no change [165, 166] or increased ghrelin levels versus baseline [167, 168]. 
 In addition to effects on energy homeostasis, ghrelin may play a role in the regulation 
of bone metabolism through its effects on growth hormone via binding to the growth 
hormone secretagogue receptor, and as a consequence, an increase in insulin-like growth 
factor-1 secretion [169]. Ghrelin may also have a role in bone metabolism independent of the 
growth hormone axis, as osteoblasts have been reported to directly respond to ghrelin with 
increased proliferation and differentiation [170]. Furthermore, ghrelin was shown to increase 
BMD in rodents independent of growth hormone signalling [171]. 
 While animal studies suggest a predominantly anabolic effect of ghrelin on bone, 
clinical findings are not yet clear. In one study, there was no significant association between 
ghrelin and BMD [172]. Conversely, another study of pre-, peri- and post-menopausal women 
found a significant positive correlation between ghrelin, oestradiol and BMD at the spine, hip 
and radius in all subjects [173]. Overnight ghrelin secretion has been found to be positively 
and significantly related to BMD in healthy adolescent women [174], but no consistent 
relationship was seen between fasting ghrelin levels and BMD in older men and women [175]. 
 In summary, although both human and animal studies point to ghrelin emerging as a 
potentially positive regulator of bone, it remains yet to be determined whether ghrelin 
contributes to changes in bone metabolism in response to bariatric surgery. 
 
Adiponectin 
Adiponectin is an adipose tissue regulatory protein that is produced by fat cells and inhibits 
fat cell synthesis [176]. Serum adiponectin levels are suppressed in obese subjects [177]. 
Adiponectin levels are negatively correlated with fat mass, with a low expression in adipose 
tissue in obese mice and humans [178, 179], and they increase with weight loss [180]. 
 Circulating adiponectin has been shown to have antiosteogenic effects on bone cells 
due to indirect induction of formation of bone-resorbing osteoclasts via stimulation of 
receptor activator of nuclear factor kappa-B ligand (RANKL) and inhibition of 
osteoprotegerin production by osteoblasts [181]. Further evidence for potential 
antiosteogenic actions of adiponectin comes from observations of its ability to bind some 
growth factors [182] and to reduce circulating insulin concentrations [183]. This would tend 
to oppose any anabolic effects of insulin on bone and other tissues. 
 Clinical studies support the data that adiponectin may have antiosteogenic effects on 
the skeleton. In a recent meta-analysis of 59 studies which examined the influence of 
adipokines and ghrelin on bone mineral density and fracture risk in healthy men and women, 
adiponectin was found to be negatively associated with BMD independently of gender, 
menopausal status and fat mass parameters [172]. A single, prospective study of 42 women 
who were investigated at 12 months after gastric bypass [58] documented a significant and 
positive correlation between circulating adiponectin levels and the reduction in BMD relative 
to baseline (r = 0.35; p < 0.05). The described effect was unrelated to baseline parameters of 
body weight or body composition, or to the gastric bypass-induced changes in these 
parameters. In another study, although adiponectin significantly increased at 6 months post-
RYGB, there was no correlation between change in adiponectin and increase in serum 
markers of bone turnover [60]. In summary although adiponectin increase induced by weight 
loss seems to favour bone loss, further studies are required to delineate the impact of 
increased adiponectin on bone–adipose axis post-bariatric surgery. 
 
Leptin 
Leptin is a cytokine-like hormone secreted by adipocytes [184]. One of the major 
determinants of leptin secretion is fat mass, with circulating leptin levels increasing with 
increasing fat mass [185]. Leptin plays a central role in the regulation of food intake and 
energy balance as it inhibits appetite and favours energy expenditure [186]. Several studies 
have shown that serum leptin concentration decreases after the massive weight reduction 
induced by bariatric surgery. These studies point to strong correlations between changes in 
serum leptin concentration with changes in BMI [187–189] as well as fat mass, serum insulin 
concentrations, and the insulin resistance index [189]. 
 Besides metabolic effects, leptin has also been purported to be a regulator of bone 
mass via direct effects on bone cells as well as via indirect effects involving the hypothalamus 
[190]. 
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 Leptin has a direct anabolic effect on bone as it stimulates bone formation by driving 
the differentiation of bone marrow stem cells into the osteoblastic (bone forming) cell lineage, 
while simultaneously inhibiting the differentiation of osteoclasts (bone-resorbing cells) [191, 192]. This effect has been reported in leptin-deficient animals [193–195]. For instance, 
peripherally administered leptin had a stimulatory effect on bone mass in leptin-deficient 
ob/ob mice [193]. 
 In contrast to the anabolic effects of leptin acting directly on bone, leptin has been 
reported to have centrally mediated antiosteogenic actions through at least two separate 
central nervous system mechanisms including activation of both sympathetic and cocaine 
amphetamine regulated transcript (CART)-responsive neurons. Leptin has also been reported 
to promote bone loss by inhibiting osteoblast proliferation and promoting receptor activator 
of RANKL expression [196]. The central antiosteogenic effect of leptin was first revealed as an 
increased trabecular bone mass observed in leptin-deficient ob/ob mice and leptin receptor-
deficient db/db mice. Moreover, hypothalamic leptin administration reduced trabecular bone 
mass in leptin-deficient and wild-type mice [190]. However, more recent work shows that the 
antiosteogenic actions of leptin are limited to trabecular bone, with leptin-deficient ob/ob 
mice exhibiting decreases in cortical bone mass [197] in conjunction with consistently 
elevated trabecular bone mass [198]. 
 Conflicting data exist for human studies investigating effects of leptin administration 
in low leptin states (i.e. congenital leptin deficiency, lipodystrophy and hypothalamic 
amenorrhoea), where varying effects on bone have been reported, ranging from net bone 
formation to no change at all [199–202]. However, the following studies shed some light on 
the possible role of leptin in the regulation of bone in humans. 
 In a recent meta-analysis of 59 studies, leptin was positively associated with BMD, 
especially in post-menopausal women, where the pooled correlation coefficient varied from 
0.18 to 0.33 [172]. Moreover, in this study, high levels of leptin were predictive of lower risk 
of vertebral and hip fractures, independent of body weight [172]. 
 Emerging clinical evidence is consistent with the possibility that the post-surgical 
reduction in circulating leptin levels could contribute to any associated bone catabolism. A 
reduction in circulating leptin levels consistently observed after bariatric surgery would lead 
to a reduction in the direct stimulatory effects of leptin on bone cells. For instance, a 
prospective study of 20 individuals [60] examined serum concentrations of bone turnover 
markers as well as leptin at 6 and 18 months after RYGB surgery. In this study, the increase in 
serum N-terminal telopeptide NTX relative to baseline levels correlated significantly with the 
corresponding decrease in serum leptin levels (r = 0.45; p = 0.04) as well as the reduction in 
BMI (r = 0.58; p = 0.009) and the increase in serum 25-hydroxy vitamin D (r = 0.43; 
p = 0.05). In multiple regression analysis, however, only the reduction in circulating leptin 
levels was a significant predictor of the increase in N-terminal telopeptide (NTX) (p = 0.016), 
suggesting that the RYGB-induced decrease in leptin may be causally related to increased 
bone turnover. 
 
Osteocalcin 
The skeleton has recently emerged as an endocrine organ, with bone cells—osteoblasts and 
osteoclasts—secreting a variety of proteins, called osteokines. Osteokines not only influence 
bone homeostasis, they also have an impact on energy and glucose homeostasis [203–207]. 
The crosstalk between the skeleton and adipose tissue thus constitutes a homeostatic 
feedback system, with adipokines and osteokines linking these tissues in an active adipose–
bone axis. 
 One important osteokine is osteocalcin. Osteocalcin is a non-collagenous protein 
marker of osteoblastic activity thought to play a role in bone mineralization and calcium 
homeostasis [205]. The role of osteocalcin in bone is not entirely understood. Previous studies 
noted an antianabolic action of osteocalcin with a mild increase in bone mass and greater 
cortical bone formation in the osteocalcin null mice [208]. 
 Recent reports have identified a crucial role for osteocalcin in energy metabolism by 
enhancing insulin secretion, insulin sensitivity and energy expenditure [209]. While 
osteocalcin can exist in two forms, gamma-carboxylated (GLA) and undercarboxylated (GLU), 
only the undercarboxylated form of this molecule appears to function as a hormone in murine 
studies. Osteocalcin knock-out mice have increased fat mass and decreased insulin sensitivity 
[210], while treatment of wild-type mice with undercarboxylated osteocalcin leads to 
decreased fat mass and improved glucose handling [206]. 
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 The above data from murine models suggest that glucose homeostasis is controlled by 
osteocalcin production and the preponderance of evidence points to this pathway being 
present in humans, although the carboxylated GLA form of osteocalcin may be more 
important in humans. The evidence of a relationship between the circulating levels of 
osteocalcin and development of dyslipidemia, metabolic syndrome, insulin resistance and 
diabetes mellitus in humans has been growing rapidly with observational data [211–214]. 
Interestingly, markers of bone turnover including osteocalcin are lower in diabetic patients 
than in normal individuals and interventions which improve glycemic control have been 
associated with an increase in serum osteocalcin [215–217]. Additional studies with larger 
cohorts and longer follow-up are needed to determine whether the increase in osteocalcin 
following weight loss reflects a change in bone formation, glucose homeostasis or both. 
However, these studies suggest that alterations in bone turnover and with it osteocalcin levels 
would impact energy and glucose homeostasis. As such, the increase in turnover following 
some bariatric surgeries would act to improve fat mass loss and glycaemic control. 
 
Sclerostin 
Sclerostin, the product of the sclerosteosis (SOST) gene, is an osteocyte secreted negative 
regulator of bone formation. Sclerostin blocks Wnt/beta-catenin signalling in cells of the 
osteoblastic lineage through the low-density lipoprotein receptor-related protein Lrp5/Lrp6 
receptor [218]. The contrasting effects of SOST knockout [219] and transgenic overexpression 
[220] on bone in mice provides compelling evidence that sclerostin secretion by osteocytes 
can control bone mass by antagonizing the effects of WNT to induce osteoblastogenesis, 
stimulate pre-osteoblast replication and inhibit osteoblast apoptosis [220–222]. As such, 
sclerostin secretion by osteocytes in the adult skeleton appears to suppress bone formation 
and promote bone resorption [223, 224]. Further evidence for this effect of sclerostin is 
provided in the human disorders of Van Buchem’s disease [225] and sclerosteosis [226], 
which exhibit loss of sclerostin expression and pathologically high bone mass. 
 Mechanical loading of bone plays a key role in determining bone mass, strength and 
size [227, 228]. The exact nature of mechanosensing in bone is not fully elucidated, but points 
towards sclerostin being a mediator of the bone response to mechanical force. This concept 
was supported by studies of SOST knockout mice that proved to be resistant to bone loss in 
the hindlimb unloading model as well as in increases in sclerostin levels in experimental 
models of skeletal unloading [229, 230]. 
 Recent human studies also support a role of sclerostin in mediating bone responses to 
mechanical unloading. Post-menopausal women long term immobilized by stroke exhibited 
significantly higher serum sclerostin levels relative to age- and gender-matched community 
controls as well as lower bone density as assessed by quantitative ultrasound measurements 
of the calcaneus [231]. These raised sclerostin levels were associated with increased 
circulating concentrations of the bone resorption marker, measured by carboxy-terminal 
telopeptide of type I collagen. These observations of hypersclerostinemia being associated 
with reduced bone formation in immobilized patients highlight the potential role of sclerostin 
in osteoporosis resulting from mechanical unloading and disuse in humans. 
 Recent research indicates that increases in circulating sclerostin levels may contribute 
to the bone loss associated with weight loss in humans, at least that which is induced by 
lifestyle interventions [232]. A study of obese (BMI ≥ 30 kg/m2) older (≥65 years) adults who 
were randomly assigned to a 1-year programme of diet, exercise, combined diet plus exercise 
or a control group examined the role of mechanical stress in modulating sclerostin levels. The 
significant weight loss (−9.6 ± 1.2 % of initial body weight) observed in the diet group was 
associated with significantly increased serum sclerostin levels over baseline values at 6 and 
12 months. Additionally, raised sclerostin levels correlated with adverse changes in hip 
geometry parameters for this group of patients. In contrast, participants who were 
randomized to the diet plus exercise intervention showed similar weight loss (−9.4 ± 0.8 % of 
initial body weight) to that observed in the diet-only group with no increase in circulating 
sclerostin levels and preserved bone quality as assessed by hip geometry parameters. Taken 
together, these results suggest that sclerostin may partially mediate bone loss and 
deterioration in bone structure in obese patients undergoing voluntary weight loss [232]. 
 In the light of the above findings, additional studies are warranted to delineate the 
possible role of sclerostin in bone loss associated with massive changes in weight loss and 
hence mechanical loading as a result of bariatric surgery. As sclerostin suppression is at least 
partially responsible for the anabolic action of mechanical loading, pharmacological 
modulation of sclerostin in osteocytes may provide a possible novel therapeutic approach 
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directed at preventing bone loss after bariatric surgery. Recently, phase II trials of sclerostin 
antibody therapy have been published, demonstrating very promising results [233]. 
 
Fractures and Bariatric Surgery 
Bone loss after bariatric surgery would be particularly important if it results in an increase in 
fracture risk. 
 Two recent papers have provided new insight into this issue. Nakamura et al. [234] 
examined the risk of fracture in patients who underwent predominantly RYGB. The 
participants aged 44 ± 10 years, 80 % of them were female, and their mean BMI was 
49 ± 8 kg/m2 were followed up over 7.7 years. The fracture rate of patients who underwent 
surgery was compared with that of the general population, matched for age and sex. This 
study found that bariatric surgery was associated with a 2.3-fold increased relative risk of any 
fracture (95 % CI 1.8–2.8), including sites considered osteoporotic (that is, hip, spine, 
humerus and wrist), although most fractures were of the hand, leg and foot. Interestingly, the 
increase in fractures was observed early after surgery, but over half of the subsequent 
fractures did not occur until 5 years following bariatric surgery. Moreover, a prior fracture 
was not predictive of a fracture after surgery in this cohort. These findings suggest that obese 
patients may have different determinants of fracture than the general population, in which a 
prior fracture strongly predicts the likelihood of experiencing a subsequent fracture. 
 These results differ from a retrospective UK study that found no significantly 
increased risk of fracture relative to controls in patients at a mean of 2.2 years after bariatric 
surgery. However, the study did demonstrate a trend towards an increased fracture risk 3–
5 years post-bariatric surgery in patients who had a greater surgery-induced decrease in BMI 
[235]. 
 The different outcomes of these two studies most likely arise from significant 
differences in their study designs. In the UK study, the majority of participants underwent 
gastric banding, with only 29 % of patients undergoing RYGB. The gastric bypass subjects 
described by Nakamura et al in the USA were heavier than those in the UK study, and they 
achieved more marked weight loss. The UK investigators matched their patients and controls 
for age, sex and weight, whereas the US study compared the fracture rate in participants with 
that of general population matched for age and sex (but not weight). Matching control groups 
to pre-surgery weight or BMI would have elucidated any bariatric surgery-induced differences 
over and above weight itself, but the US comparisons to the general population would not 
exclude obesity itself as a factor in the increased fracture risk observed. 
 Thus, further studies are urgently required to determine whether or not bariatric 
surgery is associated with an increased fracture risk, as such a finding would have important 
clinical implications for the increasing number of people undergoing bariatric surgery for the 
management of obesity. 
 The precise reasons behind the suspected increase in fracture risk in bariatric patients 
are not fully elucidated. The previously discussed study which used HR-pQCT technology to 
evaluate volumetric BMD (vBMD) of the distal radius and tibia in RYGB patients at 12 months 
post-surgery [64] indicated that these patients experienced not only cortical bone loss but also 
reduced proximal and distal cortical load shares, indicative of decreased cortical bone 
strength. Changes in bone microarchitecture in these study patients were associated with 
increased parathyroid hormone levels, which occurred despite patients taking recommended 
calcium and vitamin D supplements. The researchers concluded that the decrease in the 
cortical strength after bariatric surgery may be associated with an increased future fracture 
risk for RYGB patients, particularly in those with secondary hyperparathyroidism and more 
significant weight loss [64]. However, this remains to be verified. 
 
Summary and Conclusions 
Bariatric surgery remains the most effective treatment of severely obese patients. However, 
the potential long-term effects of bariatric surgical procedures on other outcomes including 
bone health in this unique group of people are only partially understood. 
 Despite significant improvement in weight and comorbid conditions, there is a 
growing concern that bariatric surgery may exert a negative effect on the skeleton by 
accelerating bone loss, thereby increasing bone fragility [236]. Studies to date suggest that the 
more invasive procedures such as RYGB, when compared with gastric banding, induce a 
greater weight reduction as well as bone loss that preferentially affects the hip. In extreme 
cases, the impact of RYGB on skeletal health could be significant and, if not monitored, lead 
to severe metabolic disturbances including osteomalacia. However, what is perhaps more of a 
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concern is the potential risk to bone health associated with the increasingly popular bariatric 
procedure of sleeve gastrectomy, which is steadily replacing gastric banding. This procedure 
appears to result in similar bone losses to that induced by RYGB, but long-term data are 
lacking. 
 The specific mechanisms responsible for the skeletal effects of bariatric surgery have 
not been fully elucidated and need to be further defined. However, perturbations in a number 
of gut- and adipocyte-derived hormones including PYY, GLP-1, ghrelin, adiponectin and 
leptin post-bariatric surgery may have effects on bone which appear to be predominantly 
negative. In addition, there is a lack of standardized post-operative calcium, vitamin D and 
protein dietary and supplementation protocols for these patients. Further research is required 
to determine optimum doses of nutritional supplements, which are likely to be different in 
obese bariatric patients due to underlying and surgery-induced differences in nutrient 
absorption and assimilation. 
 While much has been learned from DXA-based research, this technology is not 
without technical limitations in obese populations and during dynamic weight loss. These 
uncertainties need to be recognized and further explored and defined and studied in 
conjunction with other technologies such as pQCT that can assess site-specific bone structure, 
bone geometry and estimates of bone strength, albeit with their own limitations. 
 Finally, prospective cohort studies that assess bone changes for several years after 
bariatric procedures, at more than one site, and together with bone turnover markers and 
carefully measured hormonal parameters, should provide a higher level of evidence for 
change in bone density. These studies will help clarify any negative clinical consequences of 
these changes, including future fracture risk in this group of patients. 
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